Pharma News

Typically characterized as poisonous, corrosive and smelling of rotten eggs, hydrogen sulfide's reputation may soon get a face-lift thanks to Johns Hopkins Medicine researchers.

Bayer's head of pharmaceuticals Stefan Oelrich said Wednesday that new drugs from the company that are each projected to generate more than $1 billion in annual sales will not be enough to bridge ...

Prior to leaving the company in 2019 for competitor AstraZeneca Pharmaceuticals LP, Shafat Quadri, a former Merck & Co.

A QIMR Berghofer-led randomised controlled trial of vitamin D supplements has found they do not protect most people from developing colds, flus and other acute respiratory infections.

A major risk of being hospitalised is catching a bacterial infection.

ViiV Healthcare has bagged a marketing authorisation for a dispersible tablet formulation of its HIV-1 treatment Tivicay (dolutegravir) in paediatric patients aged at least four weeks and weig...

Gilead Sciences and Vir Biotechnology have partnered to evaluate novel therapeutic combination strategies aimed at developing a ‘functional cure’ for chronic hepatitis B virus (HBV).

Amid slower than expected rollouts for the Pfizer and Moderna COVID-19 vaccines in the U.

Sanofi agreed to buy the U.

TIANJIN, Jan.

The amyloid theory continues to grasp at life as Eli Lilly has unveiled new phase 2 data from donanemab that show it can help Alzheimer’s disease patients by clearing these plaques out of the brain.

Gilead Sciences’ Veklury, which is better known by its scientific name remdesivir, is the only antiviral drug currently approved to treat COVID-19.